Approaches to target IgE antibodies in allergic diseases

Bianca Balbino; Eva Conde; Thomas Marichal; Philipp Starkl; Laurent L Reber

doi:10.1016/j.pharmthera.2018.05.015

Approaches to target IgE antibodies in allergic diseases

Pharmacol Ther. 2018 Nov:191:50-64. doi: 10.1016/j.pharmthera.2018.05.015. Epub 2018 Jun 27.

Authors

Bianca Balbino¹, Eva Conde², Thomas Marichal³, Philipp Starkl⁴, Laurent L Reber⁵

Affiliations

¹ Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France; INSERM, U1222, Paris, France; Université Pierre et Marie Curie, Paris, France.
² Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France; INSERM, U1222, Paris, France; Université Pierre et Marie Curie, Paris, France; Neovacs SA, Paris, France.
³ GIGA-Research and Faculty of Veterinary Medicine, University of Liege, 4000, Liege, Belgium; Walloon Excellence in Life Sciences and Biotechnology, Wallonia, Belgium.
⁴ CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Austria; Department of Medicine I, Research Laboratory of Infection Biology, Medical University of Vienna, Vienna, Austria.
⁵ Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France; INSERM, U1222, Paris, France. Electronic address: laurent.reber@inserm.fr.

PMID: 29909239
DOI: 10.1016/j.pharmthera.2018.05.015

Abstract

IgE is the antibody isotype found at the lowest concentration in the circulation. However IgE can undeniably play an important role in mediating allergic reactions; best exemplified by the clinical benefits of anti-IgE monoclonal antibody (omalizumab) therapy for some allergic diseases. This review will describe our current understanding of the interactions between IgE and its main receptors FcεRI and CD23 (FcεRII). We will review the known and potential functions of IgE in health and disease: in particular, its detrimental roles in allergic diseases and chronic spontaneous urticaria, and its protective functions in host defense against parasites and venoms. Finally, we will present an overview of the drugs that are in clinical development or have therapeutic potential for IgE-mediated allergic diseases.

Keywords: Allergy; Anaphylaxis; Antibody; Asthma; Atopic dermatitis; CD23; DARPins; FcεRI; FcεRII; Immunoglobulin; Omalizumab.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Anti-Allergic Agents / administration & dosage
Anti-Allergic Agents / pharmacology
Drug Development / methods
Humans
Hypersensitivity / drug therapy*
Hypersensitivity / immunology
Immunoglobulin E / immunology*
Omalizumab / administration & dosage*
Omalizumab / pharmacology

Substances

Anti-Allergic Agents
Omalizumab
Immunoglobulin E